Current therapies for heart failure after myocardial infarction are limited and non-curative.
Although regenerative approaches are receiving significant attention, clinical efforts that …

Acute myocardial infarction and chronic heart failure rank among the major causes of
morbidity and mortality worldwide. Except for heart transplantation, current therapy options …

Background Trials investigating the role of mesenchymal stem cells (MSCs) in increasing
ejection fraction (LVEF) after acute myocardial infarction (AMI) have raised some …

Based on the increasingly understood regenerative capacity of the human heart and
vascular system, 1 cardiovascular regenerative medicine (CRM) encompasses all potential …

Cell therapy offers a promising paradigm for heart tissue regeneration. Human induced
pluripotent stem cells (hiPS) and their cardiac derivatives are emerging as a novel treatment …

Aims Intracoronary infusion of autologous nucleated bone marrow cells (BMCs) enhanced
the recovery of left ventricular ejection fraction (LVEF) after ST-segment elevation …

Myocardial infarction is a leading cause of morbidity and mortality worldwide. Although
medical and surgical treatments can significantly improve patient outcomes, no treatment …

Ischemic heart diseases (IHDs) remain major public health problems with high rates of
morbidity and mortality worldwide. Despite significant advances, current therapeutic …

Background This comprehensive systematic review and meta-analysis investigated the mid-
to long-term efficacy and safety of stem cell therapy in patients with acute myocardial …

Despite considerable advances in medicine, cardiovascular disease is still rising, with
ischemic heart disease being the leading cause of death and disability worldwide. Thus …